

The Board of Directors, meeting today under the chairmanship of Albert Saporta, approved Stallergenes' half year consolidated financial statement :
In order to pursue its development and to reach its future objectives, Stallergenes is adopting a new logo.
Further profit growth; Sales up 16%;
Profit before R&D up 19%;
Net profit (group share) up 12%;
Acceleration of R&D expenditure